Abstract:PURPOSE: Non-interventional study in outpatient, contrast-enhanced CT; 1. to determine the extent of preventive measures for risk reduction of adverse drug reactions after contrast-enhanced CT examinations. 2. to prospectively determine the incidence and severity of adverse drug reactions occurring after administration of the iso-osmolar contrast medium iodixanol. 3. to determine a possible influence of preventive measures on the incidence/severity of adverse drug reactions..MATERIALS AND METHODS: Evaluable documentation was provided for 9953 patients from 66 radiology centers across Germany. Patient characteristics, aspects of iodixanol administration, and adverse events with an at least "possible" relationship were documented on a standardized case report form (CRF) and were evaluated up to seven days after contrast medium administration.RESULTS: About 55.5 % of patients showed one or more risk factors (e. g. impaired renal function 4.4 %, diabetes mellitus 8.5 %, hypertension 20.6 %). One third of the sites did not implement any preventive measures. Patients with a known risk for an allergy-like reaction were more likely to receive pharmacologic preventive treatment (0.5 - 50.5 %). Oral hydration was the main preventive measure in patients with renal risk factors (< 8 %) followed by intravenous hydration (1 %). Adverse drug reactions, mainly hypersensitivity reactions, occurred in 77 patients (0.74 %), but were classified as serious in only 3 patients (0.03 %). No statistically significant correlation between risk factors, preventive measures, and adverse reactions could be found.CONCLUSION: The use of preventive measures for CT examinations in this outpatient setting was generally low with risk patients being pre-medicated more often, depending on their history. In the routine outpatient setting, iso-osmolar iodixanol was very well tolerated in almost 10,000 patients undergoing diagnostic CT. The rate of acute and delayed adverse reactions was low. No correlation could be found between risk factors, preventive measures and the incidence of adverse drug reactions.KEY POINTS: • Rare use of preventive measures for outpatient CT examinations.• Low rate of acute and late adverse drug reactions to iodixanol.• No correlation between risk factors, preventive measures and adverse drug reactions.

Analysis of iodixanol-induced delayed hypersensitive reactions in patients undergoing digital subtraction angiography

A Case of Severe Lethal Allergic Reaction Caused by Iodixanol After Digital Subtraction Angiography

Adverse Reactions of Iodixanol (270mg I/mL) in Coronary CT Angiography

Retrospective analysis of non-laboratory-based adverse drug reactions induced by intravenous radiocontrast agents in a Joint Commission International-accredited academic medical center hospital in China

Post-Marketing Surveillance of the Safety Profile of Iodixanol in the Outpatient CT Setting: A Prospective, Multicenter, Observational Study of Patient Risk Factors, Adverse Reactions and Preventive Measures in 9953 Patients

Renal Tolerability of Iopromide and Iodixanol in 562 Renally Impaired Patients Undergoing Cardiac Catheterisation: the Direct Study

Iodixanol activation of mast cells: Implications in the pathogenesis of iodixanol-induced delayed cutaneous adverse reactions

Retrospective Analysis of Acute Adverse Reactions of 4 Iodine Contrast Agents

Retrospective analysis of severe adverse reaction induced by iodine contrast media

Effects of a High Dose of the Contrast Medium Iodixanol on Renal Function in Patients Following Percutaneous Coronary Intervention

Hypersensitivity Reactions Induced by Iodinated Contrast Media in Radiological Diagnosis: A Disproportionality Analysis Based on the FAERS Database

Incidence of Major Adverse Cardiovascular and Cerebrovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention with Iodixanol: an Observational Postauthorization Study

Safety and efficacy of domestic iodixanol injection in interventional neuroradiology:a multicenter clinical trial

Renal adverse effect of intravenous administration of iodixanol (270mg I/ml)

Adverse Reactions Induced by Non-ionic Iodinated Contrast Agent in 20,418 Patients receiving CT Examination

Differences in Adverse Reactions Among Iodinated Contrast Media: Analysis of the KAERS Database

An Open Label, Prospective, Multicenter, Non-Interventional Study of Iodixanol 270 Mg I/mL for Use in Individuals Undergoing Computed Tomography Angiography in Real-World Clinical Practice.

A retrospective survey of delayed adverse reactions to ionic and nonionic contrast media

Safety and Diagnostic Image Quality of Ultravist<sup>®</sup> in an Unselected Sub-Set of Chinese Patients: Data Analyses from a Previous Post Marketing Surveillance

Shelling the myth: allergies to Iodine containing substances and risk of reaction to Iodinated contrast media

Clinically useful dilution factors for iodine and gadolinium contrast material: an animal model of pediatric digital subtraction angiography using state-of-the-art flat-panel detectors